N
Natalie Staplin
Researcher at University of Oxford
Publications - 87
Citations - 10575
Natalie Staplin is an academic researcher from University of Oxford. The author has contributed to research in topics: Kidney disease & Medicine. The author has an hindex of 24, co-authored 61 publications receiving 8062 citations. Previous affiliations of Natalie Staplin include University College London & University of Southampton.
Papers
More filters
Journal ArticleDOI
Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby,Wei Shen Lim,Jonathan Emberson,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,C Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J K Baillie,Richard Haynes,Martin J Landray +25 more
TL;DR: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.
Journal ArticleDOI
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
Peter Horby,M Mafham,Louise Linsell,Jennifer L Bell,Natalie Staplin,Jonathan Emberson,Martin Wiselka,Andrew Ustianowski,E Elmahi,B Prudon,Tony Whitehouse,Timothy Felton,John Williams,J Faccenda,Jonathan Underwood,J K Baillie,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Wei Shen Lim,Alan A Montgomery,Kathy Rowan,Joel Tarning,James A Watson,Nicholas J. White,Edmund Juszczak,Richard Haynes,Martin J Landray +28 more
TL;DR: In patients hospitalized with COVID-19, hydroxychloroquine was not associated with reductions in 28-day mortality but was associated with an increased length of hospital stay and increased risk of progressing to invasive mechanical ventilation or death.
Posted ContentDOI
Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report
Peter Horby,Wei Shen Lim,Jonathan Emberson,Marion Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,Christopher Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J Kenneth Baillie,Richard Haynes,Martin J Landray +25 more
TL;DR: In patients hospitalized with COVID-19, dexamethasone reduced 28-day mortality among those receiving invasive mechanical ventilation or oxygen at randomization, but not among patients not receiving respiratory support.
Journal Article
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Peter Horby,Wei Shen Lim,Jonathan Emberson,Marion Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,Christopher Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J Kenneth Baillie,Richard Haynes,Martin J Landray +25 more
TL;DR: In this paper, the authors reported the preliminary results for the comparison of dexamethasone 6 mg given once daily for up to ten days vs. usual care alone, and the primary outcome was 28-day mortality.
Journal ArticleDOI
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter Horby,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Jonathan Emberson,Adrian Palfreeman,Jason Raw,E Elmahi,B Prudon,Christopher A Green,Simon Carley,David Chadwick,Matthew N. Davies,Matt P. Wise,J Kenneth Baillie,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jefferey,Wei Shen Lim,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,Richard Haynes,Martin J Landray +25 more
TL;DR: In patients admitted to hospital with COVID-19, lopinavir–ritonavir was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.